0000950170-24-048583.txt : 20240426 0000950170-24-048583.hdr.sgml : 20240426 20240425200048 ACCESSION NUMBER: 0000950170-24-048583 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acorda Therapeutics, Inc. CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133831168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31938 FILM NUMBER: 24878247 BUSINESS ADDRESS: STREET 1: TWO BLUE HILL PLAZA CITY: PEARL RIVER STATE: NY ZIP: 10965 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: TWO BLUE HILL PLAZA CITY: PEARL RIVER STATE: NY ZIP: 10965 FORMER COMPANY: FORMER CONFORMED NAME: ACORDA THERAPEUTICS INC DATE OF NAME CHANGE: 19960222 8-K 1 acor-20240425.htm 8-K 8-K
0001008848falseNONE00010088482024-04-252024-04-25

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2024

 

 

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-31938

13-3831168

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2 Blue Hill Plaza

3rd Floor

 

Pearl River, New York

 

10965

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 914 347-4300

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)(1)

 


Name of each exchange on which registered(1)

Common Stock, par value $0.001 per share

 

ACORQ

 

N/A
(1)
On April 3, 2024, Nasdaq informed us that it was commencing delisting proceedings and our common stock stopped trading on Nasdaq and commenced trading on the OTC Pink Marketplace on April 12, 2024 under the symbol “ACORQ.” As reported herein, Nasdaq has filed a Form 25 to delist our common stock and remove such securities from registration under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). The delisting will become effective on May 5,2024 and our common stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which our common stock will remain registered under Section 12(g) of the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the “Common Stock”) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol “ACORQ.” On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which our common stock will remain registered under Section 12(g) of the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Acorda Therapeutics, Inc.

 

 

 

 

Date:

April 25, 2024

By:

/s/ Michael A. Gesser

 

 

 

Michael A. Gesser
Chief Financial Officer and Treasurer

 

 EX-101.SCH 2 acor-20240425.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 25, 2024
Entity Registrant Name Acorda Therapeutics, Inc.
Entity Central Index Key 0001008848
Entity Emerging Growth Company false
Entity File Number 001-31938
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 13-3831168
Entity Address, Address Line One 2 Blue Hill Plaza
Entity Address, Address Line Two 3rd Floor
Entity Address, City or Town Pearl River
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10965
City Area Code 914
Local Phone Number 347-4300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ACORQ
Security Exchange Name NONE
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - acor-20240425.htm 8 acor-20240425.htm acor-20240425.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "acor-20240425.htm": { "nsprefix": "acor", "nsuri": "http://www.acorda.com/20240425", "dts": { "inline": { "local": [ "acor-20240425.htm" ] }, "schema": { "local": [ "acor-20240425.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_964e98ca-b4a0-4a36-8bb3-4bb16660a032", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acor-20240425.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_964e98ca-b4a0-4a36-8bb3-4bb16660a032", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "acor-20240425.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.acorda.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-048583-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-048583-xbrl.zip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acor-20240425_htm.xml IDEA: XBRL DOCUMENT 0001008848 2024-04-25 2024-04-25 0001008848 false NONE 8-K 2024-04-25 Acorda Therapeutics, Inc. DE 001-31938 13-3831168 2 Blue Hill Plaza 3rd Floor Pearl River NY 10965 914 347-4300 false false false false Common Stock, par value $0.001 per share ACORQ false